# SYNTHESIS OF DEUTERATED MOSAPRIDE CITRATE

Shiro Kato\* and Yoshimi Hirokawa

Exploratory Research Laboratories, Dainippon Pharmaceutical

Co., Ltd., Enoki 33-94, Suita, Osaka 564, Japan

# SUMMARY


The deuterium labeled form of mosapride citrate, a potential gastroprokinetic agent, was prepared via reduction of ethyl 4-(4-fluorobenzyl)-2-morpholinecarboxylate (4) with lithium borodeuteride.

Keywords: [<sup>2</sup>H<sub>2</sub>]-mosapride; gastroprokinetic agent;

5-HT<sub>4</sub> agonist; benzamide


# INTRODUCTION

4-Amino-5-chloro-2-ethoxy-N-{[4-(4-fluorobenzyl)-2-morpholinyl]methyl}benzamide citrate (1, mosapride citrate) [1---3] is a potential gastroprokinetic agent without dopamine  $D_2$ receptor antagonistic activity. The gastroprokinetic action is accepted to be correlated with agonistic activity at a new serotonin receptor subtype (5-HT<sub>4</sub>) [4]. Mosapride citrate acts as a partial agonist for 5-HT<sub>4</sub> receptor and facilitates cholinergic transmission [5]. Clinical evaluations of 1 are ongoing. Metabolic studies required the synthesis of the deuterium labeled



CCC 0362-4803/95/100927-06 ©1995 by John Wiley & Sons, Ltd. Received 21 December 1994 Revised 28 April 1995 form of mosapride. In this paper, we describe the facile of  $[{}^{2}H_{2}]$ -mosapride citrate via reduction of ethyl 4-(4-fluorobenzyl)-2-morpholinecarboxylate (4) with lithium borodeuteride.

# RESULTS AND DISCUSSION



[<sup>2</sup>H<sub>2</sub>]-mosapride citrate

#### Scheme 1

The synthetic route is shown in Scheme 1. This route comprises the reduction of ethyl 4-(4-fluorobenzyl)-2-morpholinecarboxylate (4) with lithium borodeuteride. Beecham group reported that the reaction of 2-(benzylamino)ethanol with 2-chloroacrylonitrile gave 4-benzyl-2morpholinecarbonitrile [6]. This method was applied for the morpholine ring synthesis; the treatment of 2-[(4-fluorobenzyl)amino]ethanol (2) with 2-chloroacrylonitrile afforded the corresponding 2-cyanomorpholine 3, which was converted to the intermediate ethyl morpholine-2-carboxylate 4 in a moderate yield. The reduction of 4 with sodium borodeuteride and lithium chloride in  $C_2H_5OH$  furnished  $[2-^2H_2]$ -4-(4-fluorobenzyl)-2-hydroxymethyl-morpholine (5) in an excellent yield. Compound 5 was transformed into the phthalimide 6 using the Mitsunobu reaction [7]. The resultant 6 was treated with hydrazine to give the amine 7 in a good yield. Finally, the reaction of 7 with 4-amino-5-chloro-2-ethoxybenzoic acid [1] in the presence of 1-ethyl-3-[(3-dimethylamino)propyl]carbodiimide hydrochloride as a coupling agent, followed by the treatment of citric acid, afforded the desired [<sup>2</sup>H<sub>2</sub>]-mosapride citrate.

# EXPERIMENTAL SECTION

All melting points were determined on a Yanagimoto micromelting point apparatus and are uncorrected. Ir spectra were recorded on a Hitachi 260-10 spectrometer. Electron ionization (EI) and secondary ion (SI) mass spectra (abbreviated as EIMS and SIMS, respectively) were obtained on a JEOL JMS D-300 spectrometer or a Hitachi M-80B spectrometer. <sup>1</sup>H-NMR spectra were taken at 200 MHz with a Varian GEMINI-200 spectrometer. Chemical shifts are expressed as  $\delta$  (ppm) values with tetramethylsilane as an internal standard, and coupling constants (*J*) are given in Hz. Organic extracts were dried over anhydrous MgSO<sub>4</sub> or anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure. Merck silica gel 60 (70–230 mesh) was used for column chromatography.

Ethyl 4-(4-fluorobenzyl)-2-morpholinecarboxylate (4) A solution of 2-[(4-fluorobenzyl)amino]ethanol [8] (2, 17.0 g, 0.10 mol) and 2-chloroacrylonitrile (9.7 ml, 0.12 mol) in  $(C_2H_5)_2O$  (100 ml) was stirred at room temperature for 5 days. The solvent was evaporated to leave an oily residue, which was dissolved in 1,2-dimethoxyethane (300 ml). To the cooled solution was added potassium *tert*-butoxide (11.3 g, 0.10 mol). The mixture was stirred at room temperature for 2 h and then heated to reflux for 1h. After cooled to room temperature, saturated aqueous NaHCO<sub>3</sub> (100 ml) was added. The solution was extracted with  $(C_2H_5)_2O$  and the extract was washed with brine. The solvent was evaporated to give a pale yellow oil, which was chromatographed on silica gel with  $CHCl_3/CH_3OH = 50/1$  to afford 13.6 g (62%) of 4-(4-fluorobenzyl)-2-morpholinecarbonitrile (3) as a colorless oil. <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ : 2.39 (1H, ddd,  $J = 3.0, 9.0, 12.0, 5-H_{ax}$ ), 2.47—2.70 (2H, m), 2.76 (1H, ddd,  $J = 1.5, 4.0, 12.0, 3-H_{eq}$ ), 3.49 (1H, d,  $J = 13.0, CH_2C_6H_4F$ ), 3.57 (1H, d,  $J = 13.0, CH_2C_6H_4F$ ), 3.77 (1H, td,  $J = 3.5, 11.8, 6-H_{eq}$ ), 4.02 (1H, ddd,  $J = 3.0, 9.0, 11.8, 6-H_{ax}$ ), 4.60 (1H, t,  $J = 3.5, 11.8, 6-H_{eq}$ ), 4.02 (1H, ddd,  $J = 3.0, 9.0, 11.8, 6-H_{ax}$ ), 4.60 (1H, t,  $J = 3.5, 11.8, 6-H_{eq}$ ), 4.02 (1H, ddd,  $J = 3.0, 9.0, 11.8, 6-H_{ax}$ ), 4.60 (1H, t,  $J = 3.5, 11.8, 6-H_{eq}$ ), 4.02 (1H, ddd,  $J = 3.0, 9.0, 11.8, 6-H_{ax}$ ), 4.60 (1H, t,  $J = 3.5, 11.8, 6-H_{eq}$ ), 4.02 (1H, ddd,  $J = 3.0, 9.0, 11.8, 6-H_{ax}$ ), 4.60 (1H, t,  $J = 3.5, 11.8, 6-H_{eq}$ ), 4.02 (1H, ddd,  $J = 3.0, 9.0, 11.8, 6-H_{ax}$ ), 4.60 (1H, t,  $J = 3.5, 11.8, 6-H_{eq}$ ), 4.02 (1H, ddd,  $J = 3.0, 9.0, 11.8, 6-H_{ax}$ ), 4.60 (1H, t,  $J = 3.5, 11.8, 6-H_{eq}$ ), 4.02 (1H, ddd,  $J = 3.0, 9.0, 11.8, 6-H_{ax}$ ), 4.60 (1H, t,  $J = 3.5, 11.8, 6-H_{eq}$ ), 4.02 (1H, ddd,  $J = 3.0, 9.0, 11.8, 6-H_{ax}$ ), 4.60 (1H, t,  $J = 3.5, 11.8, 6-H_{eq}$ ), 4.02 (1H, ddd,  $J = 3.0, 9.0, 11.8, 6-H_{ax}$ ), 4.60 (1H, t,  $J = 3.5, 11.8, 6-H_{eq}$ ), 4.

2-H), 6.95-7.10 (2H, m, arom H), 7.25-7.40 (2H, m, arom H). SIMS *m*/z: 221, 220 (M<sup>+</sup>), 219. IR (neat) v cm<sup>-1</sup>: 2230 (CN).

A mixture of 3 (1.0 g, 4.5 mmol), concentrated  $H_2SO_4$  (1.3 ml), and  $C_2H_5OH$  (8 ml) was heated to reflux for 20 h and then cooled to room temperature. The solvent was evaporated to leave a residue, which was dissolved in water. The aqueous solution was basified with 20% aqueous  $K_2CO_3$  and extracted with  $(C_2H_5)_2O$ . The extract was washed with brine. The solvent was evaporated to afford an oily residue, which was chromatographed on silica gel with ethyl acetate to give 1.2 g (98%) of 4 as a colorless oil. <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ : 1.27 (3H, t, J = 7.0, OCH<sub>2</sub>CH<sub>3</sub>), 2.23-2.43 (2H, m), 2.57 (1H, m). 2.91 (1H, ddd, J = 1.3, 3.0, 10.0,  $3-H_{eq}$ ), 3.45 (1H, d, J = 13.2, CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>F), 3.54 (1H, d, J = 13.2, CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>F), 3.69 (1H, ddd, J = 3.0, 9.5, 12.0, 6-H<sub>ax</sub>), 4.02 (1H, td, J = 3.5, 12.0, 6-H<sub>eq</sub>), 4.20 (1H, m), 4.22 (2H, q, J = 7.0, OCH<sub>2</sub>CH<sub>3</sub>), 6.95-7.08 (2H, m, arom H), 7.20-7.35 (2H, m, arom H). SIMS *m*/z: 268 (MH<sup>+</sup>), 266. IR (neat) v cm<sup>-1</sup>: 1725 (COOEt).

[2-<sup>2</sup>H<sub>2</sub>]-4-(4-Fluorobenzyl)-2-hydroxymethylmorpholine (5) To a mixture of 4 (1.2 g, 4.5 mmol), lithium chloride (0.38 g, 9.0 mmol), sodium borodeuteride (0.38 g, 9.0 mmol), and anhydrous tetrahydrofuran (THF, 10 ml) was added dropwise anhydrous  $C_2H_5OH$  (10 ml) at room temperature. The mixture was stirred at the same temperature for 15 h and concentrated to dryness. The residue was dissolved in water and then extracted with CHCl<sub>3</sub>, and the extract was washed with brine. The solvent was evaporated to give a pale yellow oil, which was chromatographed on silica gel with ethyl acetate to afford 1.0 g (98%) of 5 as a colorless oil. <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ : 2.00 (1H, t-like,  $J = 10.0, 3-H_{ax}$ ), 2.19 (1H, dt,  $J = 3.5, 11.3, 5-H_{ax}$ ), 2.68—2.76 (2H, m), 3.43 (1H, d,  $J = 13.0, CH_2C_6H_4F$ ), 3.52 (1H, d,  $J = 13.0, CH_2C_6H_4F$ ), 3.65 (1H, dd, J = 2.0, 10.0, 2-H), 3.71 (1H, dt,  $J = 2.2, 11.3, 6-H_{ax}$ ), 3.90 (1H, ddd,  $J = 1.5, 3.5, 11.3, 6-H_{eq}$ ), 6.92—7.10 (2H, m, arom H), 7.21—7.36 (2H, m, arom H). EIMS *m/z*: 227 (M<sup>+</sup>), 164, 109.

[2-<sup>2</sup>H<sub>2</sub>]-*N*-[[4-(4-Fluorobenzyl)-2-morpholinyl]methyl]phthalimide (6) Dimethyl azodicarboxylate (0.64 g, 4.4 mmol) in anhydrous THF (3 ml) was added portionwise to a solution of 5 (1.0 g, 4.4 mmol), triphenylphosphine (1.2 g, 4.4 mmol), and phthalimide (0.65 g, 4.4 mmol) in THF (20 ml) at 0°C. The mixture was stirred at room temperature for 15 h and concentrated to dryness. The residue was dissolved in CHCl<sub>3</sub> and washed successively with water and brine. The solvent was evaporated to leave a solid, which was recrystallized from CH<sub>3</sub>OH to give 1.5 g (96%) of 6, mp 151—152°C. <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ : 2.05 (1H, t-like, J =

11.0,  $3-H_{ax}$ ), 2.21 (1H, t,  $J = 10.0, 5-H_{ax}$ ), 2.57 (1H, d,  $J = 11.0, 5-H_{eq}$ ), 2.78 (1H, d,  $J = 10.0, 3-H_{eq}$ ), 3.3—3.7 (3H, m,  $CH_2C_6H_4F$ , 2-H), 3.8—4.0 (2H, m), 6.95—7.1 (2H, m, arom H), 7.2—7.4 (2H, m, arom H), 7.67—7.8 (2H, m, arom H), 7.8—7.93 (2H, m, arom H). SIMS *m/z*: 357 (MH<sup>+</sup>), 313, 208, 136, 109. IR (KBr) v cm<sup>-1</sup>: 1755, 1700 [N(CO)<sub>2</sub>]. Anal. Calcd for  $C_{20}H_{17}D_2FN_2O_3$ : C, 67.40; H, 4.81; D, 1.13; F, 5.33; N, 7.86. Found: C, 67.41; H, 4.70; D, 1.07; F, 5.50; N, 7.83.

[2-<sup>2</sup>H<sub>2</sub>]-2-(Aminomethyl)-4-(4-fluorobenzyl)morpholine (7) The mixture of 6 (1.5 mmol), 100% hydrazine monohydrate (0.32 g, 6.4 mmol), and  $C_2H_5OH$  (15 ml) was heated to reflux for 4 h and cooled to room temperature. After the reaction mixture was diluted with CHCl<sub>3</sub>, the insoluble materials were filtered off. The filtrate was washed successively with a small amount of water and brine. The solvent was evaporated to leave 0.92 g of 7 as a pale yellow oil. <sup>1</sup>H-NMR (CDCl<sub>3</sub>) &: 1.63 (2H, br. s, NH<sub>2</sub>), 1.85 (1H, dd,  $J = 10.0, 11.3, 3-H_{ax}$ ), 2.15 (1H, dd,  $J = 3.5, 11.3, 5-H_{ax}$ ), 2.58—2.76 (2H, m), 3.45 (2H, s, CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>F), 3.49 (1H, dd, J = 2.0, 10.0, 2-H), 3.67 (1H, dt,  $J = 2.5, 11.3, 6-H_{ax}$ ), 3.87 (1H, ddd,  $J = 1.5, 3.5, 11.3, 6-H_{eq}$ ), 6.92—7.07 (2H, m, arom H), 7.20—7.36 (2H, m, arom H). SIMS *m/z*: 227 (MH<sup>+</sup>), 194, 109.

<sup>[2</sup>H<sub>2</sub>]-Mosapride citrate The mixture of 4-amino-5-chloro-2-ethoxybenzoic acid [1] (0.86 g, 4.0 mmol), 7 (0.9 g, 4.0 mmol), 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride (0.84 g, 4.4 mmol), CH<sub>2</sub>Cl<sub>2</sub> (30 ml) was stirred at room temperature for 4 h. The reaction mixture was washed successively with water, 10% aqueous NaOH, water, and brine. The solvent was evaporated to give a pale yellow oil, which was chromatographed on silica gel with  $CHCl_3/CH_3OH = 12/1$  to furnish 1.6 g (93%) of  $[^{2}H_{2}]$ -mosapride as a colorless oil. Mosapride was converted to the citrate in the usual manner. Mp 131.5-132.5°C (CH<sub>3</sub>OH- $C_{2}H_{5}OH$ ). <sup>1</sup>H-NMR (DMSO- $d_{6}$ )  $\delta$ : 1.38 (3H, t, J = 7.0, OCH<sub>2</sub>CH<sub>3</sub>), 1.96 (1H, t-like, J = 11.0,  $3-H_{ax}$ , 2.15 (1H, dt,  $J = 2.0, 11.0, 5-H_{ax}$ ), 2.64 (2H, d, J = 15.5, citric acid), 2.73 (2H, J = 15.5, citric acid), 3.15–3.65 (2H, m), 3.54 (2H, s,  $CH_2C_6H_4F$ ), 3.84 (1H, d, J = 11.5, 6-H), 4.05 (2H,  $q, J = 7.0, OCH_2CH_3$ , 5.94 (2H, s, NH<sub>2</sub>), 6.46 (1H, s, arom 3-H), 7.1-7.23 (2H, m, arom H), 7.28-7.4 (2H, m, arom H), 7.70 (1H, s, arom 6-H), 8.04 (1H, s, CONH). SIMS m/z: 424 (MH<sup>+</sup>). IR (KBr) v cm<sup>-1</sup>: 3360, 1720, 1630, 1580, 1540. Anal. Calcd for  $C_{21}H_{23}ClD_2FN_3O_3$ . C<sub>6</sub>H<sub>8</sub>O<sub>7</sub>: C, 52.64; H, 5.07; Cl, 5.75; D, 0.65; F, 3.08; N, 6.82. Found: C, 52.39; H, 4.99; Cl, 5.52; D. 0.84; F. 3.08; N. 6.75.

### ACKNOWLEDGMENT

We are grateful to the staff of the Analytical Chemistry Division of Exploratory Research Laboratories, Dainippon Pharmaceutical Company, for elemental analyses and spectral measurements.

## REFERENCES

- Kato S., Morie T., Kon T., Yoshida N., Karasawa T., and Matsumoto J.— J. Med. Chem. <u>34</u>: 616 (1991)
- Yoshida N., Omoya H., Oka M., Furukawa K., Ito T., and Karasawa T. Arch. Int. Pharmacodyn. Ther. <u>300</u>: 51 (1989)
- 3. Yoshida N., Kato S., and Ito T. Drugs Future 18: 513 (1993)
- Dumis A., Sebben M., and Bockaert J. —Naunyn-Schmiedeberg's Arch. Pharmacol. <u>340</u>: 403 (1989)
- 5. Yoshida N. and Ito T. Neurogastroenterol. Mot. 6: 197 (1994)
- Beecham Group PLC, Jpn. Kokai Tokkyo Koho JP 62 30,785 (87 30,785) [Chem. Abstr., <u>106</u>: 213963k (1987)
- 7. Mitsunobu O. Synthesis 1981: 1
- Kato S., Morie T., Harada H., Yoshida N., and Matsumoto J.— Chem. Pharm. Bull. <u>42</u>: 877 (1994)